2 Matching Annotations
  1. Jul 2018
    1. On 2015 Nov 29, Mauro De Rosa commented:

      Replacing branded medicines with generic ones

      In most countries, regulatory agencies have the responsibility of indicating the situations in which branded medicines can be substituted by equivalent ones (i.e. generics). In Italy, these regulatory recommendations have been issued by our national medicine agency (AIFA) by indicating the exceptions, i.e. those cases where a branded medicine cannot be replaced by the equivalent counterpart. A total of six such cases have been identified in Italy, which included the following agents: levetiracetam and topiramate (1), levotyroxine (2), cyclosporine (3), metformine + glibenclamide (4), tacrolimus (5).

      References

      1. AIFA website - Specialità medicinali contenenti Levetiracetam e Topiramato (17/09/2012), http://www.agenziafarmaco.gov.it/it/content/specialità-medicinali-contenenti-levetiracetam-e-topiramato-17092012); accessed 3.9.2015

      2. AIFA website - http://www.agenziafarmaco.gov.it/it/content/precisazione-aifa-sulla-prescrizione-base-di-levotiroxina-15122014 accessed 30.10.2015

      3. AIFA website - http://www.agenziafarmaco.gov.it/it/content/precisazioni-aifa-su-specialità-medicinali-contenenti-ciclosporina-15042015 Precisazioni AIFA del 15 aprile 2015 su specialità medicinali contenenti ciclosporina accessed 3.9.2015

      4. AIFA website http://www.agenziafarmaco.gov.it/it/content/liste-di-trasparenza-metformina-e-glibenclamide-500-mg-5-mg accessed 3.9.2015

      5. AIFA website http://www.agenziafarmaco.gov.it/it/content/precisazioni-aifa-su-specialità-medicinali-contenenti-tacrolimus accessed 3.9.2015


      This comment, imported by Hypothesis from PubMed Commons, is licensed under CC BY.

  2. Feb 2018
    1. On 2015 Nov 29, Mauro De Rosa commented:

      Replacing branded medicines with generic ones

      In most countries, regulatory agencies have the responsibility of indicating the situations in which branded medicines can be substituted by equivalent ones (i.e. generics). In Italy, these regulatory recommendations have been issued by our national medicine agency (AIFA) by indicating the exceptions, i.e. those cases where a branded medicine cannot be replaced by the equivalent counterpart. A total of six such cases have been identified in Italy, which included the following agents: levetiracetam and topiramate (1), levotyroxine (2), cyclosporine (3), metformine + glibenclamide (4), tacrolimus (5).

      References

      1. AIFA website - Specialità medicinali contenenti Levetiracetam e Topiramato (17/09/2012), http://www.agenziafarmaco.gov.it/it/content/specialità-medicinali-contenenti-levetiracetam-e-topiramato-17092012); accessed 3.9.2015

      2. AIFA website - http://www.agenziafarmaco.gov.it/it/content/precisazione-aifa-sulla-prescrizione-base-di-levotiroxina-15122014 accessed 30.10.2015

      3. AIFA website - http://www.agenziafarmaco.gov.it/it/content/precisazioni-aifa-su-specialità-medicinali-contenenti-ciclosporina-15042015 Precisazioni AIFA del 15 aprile 2015 su specialità medicinali contenenti ciclosporina accessed 3.9.2015

      4. AIFA website http://www.agenziafarmaco.gov.it/it/content/liste-di-trasparenza-metformina-e-glibenclamide-500-mg-5-mg accessed 3.9.2015

      5. AIFA website http://www.agenziafarmaco.gov.it/it/content/precisazioni-aifa-su-specialità-medicinali-contenenti-tacrolimus accessed 3.9.2015


      This comment, imported by Hypothesis from PubMed Commons, is licensed under CC BY.